Should we consider a new classification of diabetes influenced by therapeutic decisions?

Authors: Jan Škrha
Authors‘ workplace: III. interní klinika 1. LF UK a VFN v Praze
Published in: Vnitř Lék 2016; 62(Suppl 4): 113-118
Category: Reviews


The growing number of diabetic patients in the whole world causes the problems to allocate some patients into the respective type of diabetes related to the present classification. B cell is considered as the central cause of diabetes and its intracellular impairment is practically the same in both types of diabetes. Diabetic patients will be recognized according to the state of impaired B cell. The antidiabetic drugs will be selected according to their effect protecting the B cells. Some antidiabetic drugs will be used more frequently in type 1 diabetes as well.

Key words:
antidiabetic drugs protecting B cell – B cell apoptosis – diabetes classification


1. Škrha J. Cesta diabetologie aneb jak vše začíná a končí? Maxdorf: Praha 2014. ISBN 978–80–7345–385–5.

2. Wang X, Tan H. Male predominance in ketosis-prone diabetes mellitus (Review). Biomed Rep 2015; 3(4): 439–442.

3. Jha S, Waghdhare S, Siddiqui S et al. First Identification of Flatbush Diabetes in Patients of Indian Origin. Diabetes Care 2015; 38(12): e164-e165. Dostupné z DOI: <–1209>.

4. Škrha J. Patogeneze diabetes mellitus 1. a 2. typu v roce 2011 – jednotící model poruchy glykoregulace. Vnitř Lék 2011; 57(11): 949–953.

5. Schwartz SS, Epstein S, Corkey BE et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centri classification schema. Diabetes Care 2016; 39(2): 179–186. Dostupné z DOI: <–1585>.

6. Basile KJ, Guy VC, Schwartz S et al. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep 2014; 14(11): 550. Dostupné z DOI: <–014–0550–9>.

7. Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am 2015; 99(1): 1–16. Dostupné z DOI: <>.

8. Leslie RD, Palmer J, Schloot NC et al. Diabetes at the corssroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 2016; 59(1): 13–20.

9. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773–795. Dostupné z DOI: <–9028>.

10. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1 and type 2 diabetes mellitus and obesity. Rev Endocrinol Metab Disord 2015; 16(1): 55–65. Dostupné z DOI: <–015–9309–0>.

11. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G et al. Molecular and cellular mechanisms linking inflammation to insulin resistance and beta-cell dysfunction. Transl Res 2016; 167(1): 228–256. Dostupné z DOI: <>.

12. Subauste A, Gianani R, Chang AM et al. Islet autoimmunity identifies a unique pattern of impaired pancreatic beta-cell function, markedly reduced pancreatic beta-cell mass and insulin resistence in clinically diagnosed type 2 diabetes. PLoSOne 2014; 9(9): e106537. Dostupné z DOI: <>.

13. Maedler K, Carr RD, Bosco D et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90(1): 501–506.

14. DelGuerra S, Grupillo M, Masini M et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diab Metab Res Rev 2007; 23(3): 234–238.

15. Juhl CB, Porksen N, Hollingdal M et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care 2000; 23(5): 675–681.

16. Matsuda T, Takahashi H, MiedaY et al. Regulation of pancreatic beta cell mass by cross-interaction between CCAAT enhancer binding protein beta induced by endoplasmic reticulum stress and AMP-activated protein kinase activity. PLoSOne 2015; 10(6): e0130757. Dostupné z DOI: <>.

17. Dai YL, Huang Su-Ling, Leng Y. AICAR and Metformin Exert AMPK-dependent Effects on INS-1E Pancreatic β-cell Apoptosis via Differential Downstream Mechanisms. Int J Biol Sci 2015; 11(11): 1272–1280. Dostupné z DOI: <>.

18. Simon-Szabo L, Kokas M, Mandl J et al. Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS ONE 2014; 9(6): e97868. Dostupné z DOI: <>.

19. Saitoh Y, Chun-ping C, Noma K et al. Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. Diab Obes Metab 2008; 10(7): 564–573.

20. Puddu A, Sanguineti R, Durante A et al. Pioglitazone attenuates the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T15. Regulatory Peptides 2012; 177(1–3): 79–84. Dostupné z DOI: <>.

21. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diab Obes Metab 2008; 10(8): 617–625.

22. Wang A, Li X, Zheng Y et al. Thiazolidinediones protect mouse pancreatic beta-cells directly from cytokine-induced cytotoxicity through PPAR gamma-dependent mechanisms. Acta Diabetol 2013; 50(2): 163–173. Dostupné z DOI: <–010–0239–8>.

23. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Molec Cell Endocrinol 2009; 297(1–2): 127–136. Dostupné z DOI: <>.

24. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidylpeptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146(5): 717–727.

25. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55(6): 1695–1704.

26. Chen J, Couto FM, Minn AH et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006; 346(3): 1067–1074.

27. Shimoda M, Kanda Y, Hamamoto S et al. The guman glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011; 54(5): 1098–1108. Dostupné z DOI: <–011–2069–9>.

28. Chang TJ, Tseng HC, Liu MW et al. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation. Sci Rep 2016; 6: 23403. Dostupné z DOI: <>.

29. Shah P, Ardestani A, Dharmadhikari G. et al. The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab 2013; 98(7): E1163-E1172. Dostupné z DOI: <–1029>.

30. Kim JY, Lim DM, Park HS et al. Exendin-4 protects against sulfonylurea-induced beta-cell apoptosis. J Pharmacol Sci 2012; 118(1): 65–74.

31. Cernea S, Raz I. Therapy in the early stage: Incretins. Diabetes Care 2011; 34(Supp 2): S264-S271. Dostupné z DOI: <>.

32. Hansen HH, Jelsing J, Hansen CF et al. The sodium glucose cotransporter Type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat. J Pharmacol Exp Therap 2014; 350(3): 657–664. Dostupné z DOI: <>.

33. Macdonald FR, Peel JE, Jones HB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diab Obes Metab 2010; 12(11): 1004–1012. Dostupné z DOI: <–1326.2010.01291.x>.

34. Okauchi S, Shimoda M, Obata A et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun 2016; 470(3): 772–782. Dostupné z DOI: <>.

35. Jurczak MJ, Lee HY, Birkenfeld AL et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60(3): 890–898. Dostupné z DOI: <–1328>.

36. Cheng STW, Chen LH, Li SYT et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in Type 1 diabetes. PLoSOne 2016; 11(1): e0147391. Dostupné z DOI: <>.

37. Ogata H, Seino Y, Harada N et al. K-ATP channel as well as SGLT1participates in GIP secretion in the diabetic state. J Endocrinol 2014; 222(2): 191–200. Dostupné z DOI: <–0161>.

38. Johnson JD, Bernal-Mizrachi E, Alejandro EU et al. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proc Nat Acad Sci US 2006; 103(51): 19575–19580.

39. Kautz S, van Buerck L, Schuster M et al. Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2 C95S). Diabetologia 2012; 55(2): 382–391. Dostupné z DOI: <–011–2362–7>.

40. Naik RG, Palmer JP. Preservation of beta-cell function in type 1 diabetes. Diabetes Rev 1999; 7(3): 154–182.

41. Skyler JS. Prevention and reversal of type 1 diabetes – past challenges and future opportunities. Diabetes Care 2015; 38(6): 997–1007. Dostupné z DOI: <–0349>.

42. Owens DR. Clinical evidence for the earlier initiation of insulin therapy in Type 2 diabetes. Diabetes Technol Therap 2013; 15(9): 776–785. Dostupné z DOI: <>.

43. Kikawa K, Sakano D, Shiraki N et al. Beneficial effect of insulin treatment on islet transplantation outcomes in Akita mice. PLoS ONE 2014; 9(4): e95451. Dostupné z DOI: <>.

Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue Suppl 4

2016 Issue Suppl 4

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account